Prestige Consumer Healthcare Inc. Announces New $25 Million Share Repurchase Program, Participation in the Raymond James Institutional Investors Conference TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)

Prestige Consumer Healthcare Inc. Announces New $25 Million

Share Repurchase Program, Participation in the Raymond James Institutional Investors Conference

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-March 2, 2020-- Prestige

Consumer Healthcare Inc. (NYSE:PBH) today announced that the Company's Board of Directors authorized the repurchase of up

to $25.0 million of the Company's issued and outstanding common stock. Separately, the Company plans to present at the Raymond

James Institutional Investors Conference at 8:40 a.m. ET today, March 2nd.

Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare,

said, "Today's share repurchase program announcement demonstrates the Board and management's continued confidence

in the long-term growth prospects of Prestige and our proven three pillar strategy focused around organic growth, free cash flow

and capital allocation to drive shareholder value. The authorized repurchases are part of the ongoing commitment to a disciplined

and opportunistic capital deployment strategy that is enabled by our robust financial profile. We look forward to discussing our

business strategy in greater detail at the Raymond James conference later today."

Share Repurchase Details

Under the approved authorization, the Company may purchase common

stock through March 2021 utilizing one or more open market transactions, transactions structured through investment banking institutions,

in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with

the applicable rules and regulations of the Securities and Exchange Commission.

The timing of the purchases and the amount of stock repurchased

is subject to the Company's discretion and will depend on market and business conditions, applicable legal and credit requirements

and other corporate considerations, including the Company's historical strategy of pursuing accretive acquisitions and deleveraging.

41st Annual Raymond James Conference

The Company is presenting at the Raymond James 41st

Annual Institutional Investors Conference today, March 2nd at 8:40 a.m. ET. The presentation will be webcast live and

can be accessed on the Company's website, www.prestigeconsumerhealthcare.com, and will remain available as an archived replay

for one week following the presentation date.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets,

sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia,

and in certain other international markets. The Company's diverse portfolio of brands include Monistat and Summer's

Eve women's health products, BC and Goody's pain relievers, Clear Eyes eye care products, DenTek specialty

oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic

and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter

products, Boudreaux's Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, Gaviscon

antacid in Canada, and Hydralyte rehydration products and the Fess line of nasal and sinus care products in Australia.

Visit the Company's website at www.prestigeconsumerhealthcare.com.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements"

within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by

the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the

use of forward-looking terminology such as "assumptions," "target," "guidance," "prospects,"

"outlook," "plans," "projection," "may," "will," "would," "expect,"

"intend," "estimate," "anticipate," "believe", "potential," or "continue"

(or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements"

include, without limitation, statements regarding the the Company's expectations regardingorganic growth and free cash flow, the

Company's disciplined capital allocation, the Company's ability to create value for its stakeholders, and the timing

and amount of the Company's share repurchases. These statements are based on management's estimates and assumptions with

respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult

to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact

of the Company's advertising and promotional and new product development initiatives, customer inventory management initiatives,

general economic and business conditions, fluctuating foreign exchange rates, consumer trends, competitive pressures, the impact

of the transition to a new third party logistics provider, the ability of the Company's third party manufacturers and logistics

providers and suppliers to meet demand for its products and to reduce costs, market conditions, and the Company's strategy

of pursuing acquisitions and deleveraging. A discussion of other factors that could cause results to vary is included in the Company's

Annual Report on Form 10-K for the year ended March 31, 2019 and other periodic reports filed with the Securities and Exchange

Investor Relations Contact

Phil Terpolilli, CFA, 914-524-6819